Claritas Rx Launches Data and Consent Platform to Boost Specialty Drug Adherence
Event summary
- Claritas Rx introduced Foundational Data Aggregation with Consent Clearinghouse™, aiming to improve first fill rates and long-term persistence for specialty/rare disease brands.
- The solution achieves 95%+ match rates across patients, HCPs, and payers using proprietary Entity Mastering and Reconciliation engine.
- Early adopters report 12%-40% higher consent fill rates and 11% stronger patient persistence.
- Platform ensures compliance with HIPAA, HITECH, GDPR, and SOC 2 standards.
The big picture
Claritas Rx's launch addresses persistent challenges in specialty drug adherence, where fragmented data and inconsistent consent processes often disrupt patient care. The solution aligns with broader industry trends toward data unification and AI-driven analytics in healthcare, potentially setting a new standard for patient journey management.
What we're watching
- Adoption Pace
- How quickly specialty and rare disease brands integrate this solution into their operations.
- Competitive Response
- Whether existing data platforms will develop similar consent management capabilities.
- Regulatory Scrutiny
- The extent to which healthcare regulators examine this type of centralized patient consent system.
Related topics